Nicole DeMars

Pre-Market Investor’s Alert: BHP Billiton Limited (ADR)(NYSE:BHP), Biogen Inc(NASDAQ:BIIB)

BHP Billiton Limited (ADR)(NYSE:BHP) stock dropped -2.33% in today’s pre market session with the price of $28.95. Over the last one month and over the past three months, BHP Billiton Limited shares gained 12.91% and 9.98%, respectively. Furthermore, the stock has gained 16.50% since the start of this year. The company’s shares are trading 6.23% above their 50-day moving average. Additionally, BHP Billiton Limited has an RSI of 62.40 and beta of 1.49.

BHP Billiton Limited discovers, acquires, develops, and markets natural resources worldwide. It operates through Petroleum and Potash, Copper, Iron Ore, and Coal segments. The company explores for, develops, produces, and markets oil and gas with operating assets in the deep water Gulf of Mexico, Western Australia, Trinidad and Tobago, the United Kingdom, and Pakistan; and owns the Jansen potash project located in the Saskatchewan potash basin in Canada. It also explores for copper, silver, lead, zinc, molybdenum, uranium, gold, iron ore, and seaborne metallurgical and thermal coal. The company was formerly known as BHP Limited and changed its name to BHP Billiton Limited in July 2001. BHP Billiton Limited was founded in 1851 and is headquartered in Melbourne, Australia. BHP Billiton Limited operates as a subsidiary of BHP Billiton Group.

Biogen Inc. (NASDAQ:BIIB) stock on Friday’s pre market session gained 1.14% at price of $257.07. Over the last one month and the previous three months, Biogen Inc’s shares dropped -5.92% and ticked down -0.58%, respectively. Additionally, the stock has plunged -17.03% since the beginning of 2016. The company’s shares are trading above their 50-day and 200-day moving averages by -6.37% and -8.77%, respectively.

June 7, 2016, Biogen (BIIB) reported top-line results from the Phase 2 SYNERGY study evaluating opicinumab (anti-LINGO-1), an investigational, fully human monoclonal antibody being developed as a potential neuroreparative therapy in people with relapsing forms of multiple sclerosis (RMS). In the study, opicinumab missed the primary endpoint, a multicomponent measure evaluating improvement of physical function, cognitive function, and disability. However, evidence of a clinical effect with a complex, unexpected dose-response was observed.

“It is only through taking thoughtful, calculated risks that we can bring major advances to patients,” said Alfred Sandrock, M.D., Ph.D., executive vice president and chief medical officer at Biogen. “Achieving repair of the human central nervous system through remyelination would be a substantial achievement, and while we missed the primary endpoint, the SYNERGY study results suggest evidence of a clinical effect of opicinumab. Due to the complex nature of the data set, we continue to analyze the results to inform the design of our next study.”

Opicinumab also did not meet the secondary efficacy endpoint in SYNERGY, which evaluated the slowing of disability progression. Safety and pharmacokinetics (PK) were also assessed as secondary endpoints. Opicinumab was generally well-tolerated and the safety profile was consistent with what has been observed in prior studies. Opicinumab showed a linear, well-behaved PK profile over the studied dose range. SYNERGY results will be presented at future medical meetings.

Latest Celldex Therapeutics, Inc. (NASDAQ:CLDX) Target Price Suggests Stock Is Worth $14.18/Share

Celldex Therapeutics, Inc. (CLDX) up 3.74 per cent in the past week, is under coverage of 11 analysts who collectively recommend a hold rating on stock. 6 of the analysts have a buy or better rating; the 0 sells versus 0 underperforms. The 11 equity analysts who rate the stock have an average target price at $14.18, with individual targets ranging between $3 and $42. The shares closed last trade at $4.72, implying that analysts see shares rising about 200.42 per cent in 12 months’ time.

Insider Activity: Insiders look mixed about the prospects of the company that they seem to trade shares both ways while they are -69.9 down so far this year. A Sr. VP & CFO at Celldex Therapeutics, Inc. (CLDX) sold shares in the company in a transaction completed on Monday November 23, 2015. Catlin Avery W offloaded 25,000 shares in the company at an average price of $18 and ended up generating $450,000 in proceeds. Catlin Avery W retains 35,109 shares in the company after this transaction. A Director in the company, Ellberger Larry, on Tuesday August 25, 2015 spent $70,000 from the purchase of 5,000 shares at $18 each. Insiders are expected to know better about the health and prospects of their company, which is why insiders’ move deserves attention.

Earnings Roundup: In the last fiscal quarter alone, Celldex Therapeutics, Inc. generated around $1.3M in revenue. That compares with the consensus estimate $860000. For the prior quarter revenue for the company hit $1.79M, with earnings at -$0.33/share.

Analyst Coverage: Jefferies has been a brokerage house following shares of Celldex Therapeutics, Inc. (CLDX), so its rating change is noteworthy. The stock was downgraded to Hold from Buy, wrote analysts at Jefferies, in a note issued to clients on Tuesday March 08, 2016. There was another key note issued by Leerink Partners on Monday March 07, 2016. The firm lowered its rating on CLDX from Outperform to Mkt Perform.

Price Momentum: Despite the 1.29% increase in value, the stock’s new closing price represents a -83.19% fall in value from company’s one year high of $28.08. The stock is currently holding below its 50 day moving average of $13.37 and above its 200 day moving average of $4.1. Over the last three months and over the last six months, the shares of Celldex Therapeutics, Inc. (CLDX), have changed -52.28% and 8.06%, respectively.

 

DDR Corp. (NYSE:DDR) Stock Declines, Analysts: Hold Rating

DDR Corp. (DDR) down -0.06 per cent in the past week, is under coverage of 21 analysts who collectively recommend a hold rating on stock. 4 of the analysts have a buy or better rating; the 0 sells versus 0 underperforms. The 18 equity analysts who rate the stock have an average target price at $18.17, with individual targets ranging between $16 and $20. The shares closed last trade at $17.2, implying that analysts see shares rising about 5.64 per cent in 12 months’ time.

Insider Activity: Insiders look pessimistic about the prospects of the company that they seem to offload shares while they are 2.14 up so far this year. A Sr. Exec. Vice President at DDR Corp. (DDR) sold shares in the company in a transaction completed on Thursday May 05, 2016. Freddo Paul W offloaded 28,939 shares in the company at an average price of $18 and ended up generating $520,900 in proceeds. Freddo Paul W retains 204,621 shares in the company after this transaction. A Director in the company, Roulston Scott D, on Wednesday February 17, 2016 collected $48,900 from the sale of 3,000 shares at $18 each. Insiders are expected to know better about the health and prospects of their company, which is why insiders’ move deserves attention.

Earnings to Watch: Investors considering DDR stock at the going market price of $17.2/share should know the stock will next release quarterly results for the June 2016 quarter. For the reporting quarter, analysts expect the company to deliver $0.31 in earnings per share (EPS). That would represent a 0% year-over-year decrease. Revenue for the same period is expected to arrive at $243.03M.

Earnings Roundup: In the last fiscal quarter alone, DDR Corp. generated around $246.24M in revenue and net income of $0.31/share. That compares with the consensus estimate $246.91M and $0.3/share, respectively. For the prior quarter revenue for the company hit $246.53M, with earnings at $0.31/share.

Analyst Coverage: KeyBanc Capital Mkts has been a brokerage house following shares of DDR Corp. (DDR), so its rating change is noteworthy. The stock was upgraded to Overweight from Sector Weight, wrote analysts at KeyBanc Capital Mkts, in a note issued to clients on Friday April 15, 2016. There was another key note issued by Mizuho on Thursday April 14, 2016. The firm launched coverage on DDR at Neutral.

Price Momentum: Despite the -1.21% decrease in value, the stock’s new closing price represents a -7.48% fall in value from company’s one year high of $18.59. The stock is currently holding above its 50 day moving average of $-1.78 and below its 200 day moving average of $17.53. Over the last three months and over the last six months, the shares of DDR Corp. (DDR), have changed 3.09% and 17%, respectively.

Immunomedics Inc. (NASDAQ:IMMU) Earns Consensus Buy Rating

Immunomedics Inc. (IMMU) down -26.65 per cent in the past week, is under coverage of 2 analysts who collectively recommend a buy rating on stock. 2 of the analysts have a buy or better rating; the 0 sells versus 0 underperforms. The 1 equity analysts who rate the stock have an average target price at $5, with individual targets ranging between $5 and $5. The shares closed last trade at $3.66, implying that analysts see shares rising about 36.61 per cent in 12 months’ time.

Insider Activity: Insiders look pessimistic about the prospects of the company that they seem to offload shares while they are 19.22 up so far this year. A President and CEO at Immunomedics Inc. (IMMU) sold shares in the company in a transaction completed on Wednesday June 08, 2016. Goldenberg Cynthia L offloaded 353,010 shares in the company at an average price of $3.88 and ended up generating $1,369,680 in proceeds. Goldenberg Cynthia L retains 5,874,532 shares in the company after this transaction. A CSO & Chairman of the BOD in the company, Goldenberg David M, on Wednesday June 08, 2016 collected $1,369,680 from the sale of 353,010 shares at $3.88 each. Insiders are expected to know better about the health and prospects of their company, which is why insiders’ move deserves attention.

Earnings to Watch: Investors considering IMMU stock at the going market price of $3.66/share should know the stock will next release quarterly results for the June 2016 quarter. For the reporting quarter, analysts expect the company to deliver -$0.11 in earnings per share (EPS). That would represent a -15.38% year-over-year decrease. Revenue for the same period is expected to arrive at $1.2M.

Analyst Coverage: Jefferies has been a brokerage house following shares of Immunomedics Inc. (IMMU), so its rating change is noteworthy. The stock was upgraded to Buy from Hold, wrote analysts at Jefferies, in a note issued to clients on Friday May 06, 2016. There was another key note issued by Jefferies on Wednesday July 29, 2015. The firm lowered its rating on IMMU from Buy to Hold.

Price Momentum: Despite the -5.67% decrease in value, the stock’s new closing price represents a -32.72% fall in value from company’s one year high of $5.44. The stock is currently holding below its 50 day moving average of $3.79 and below its 200 day moving average of $3.91. Over the last three months and over the last six months, the shares of Immunomedics Inc. (IMMU), have changed 35.24% and 2.88%, respectively.

 

Dermira, Inc. (NASDAQ:DERM) Stock Declines, Analysts: Buy Rating

Dermira, Inc. (DERM) down -6.88 per cent in the past week, is under coverage of 0 analysts who collectively recommend a buy rating on stock. 0 of the analysts have a buy or better rating; the 0 sells versus 0 underperforms. The 5 equity analysts who rate the stock have an average target price at $42.6, with individual targets ranging between $40 and $47. The shares closed last trade at $29.8, implying that analysts see shares rising about 42.95 per cent in 12 months’ time.

Insider Activity: Insiders look pessimistic about the prospects of the company that they seem to offload shares while they are -13.9 down so far this year. A CEO & Chairman of the Board at Dermira, Inc. (DERM) sold shares in the company in a transaction completed on Wednesday June 01, 2016. Wiggans Thomas G offloaded 11,000 shares in the company at an average price of $31.57 and ended up generating $347,270 in proceeds. Wiggans Thomas G retains 224,932 shares in the company after this transaction. A Chief Medical Officer in the company, Bauer Eugene A, on Wednesday June 01, 2016 collected $79,130 from the sale of 2,500 shares at $31.57 each. Insiders are expected to know better about the health and prospects of their company, which is why insiders’ move deserves attention.

Earnings Roundup: In the last fiscal quarter alone, Dermira, Inc. generated around $0 in revenue and net income of -$0.95/share. That compares with the consensus estimate $0 and -$0.94/share, respectively. For the prior quarter revenue for the company hit $0, with earnings at -$1.04/share.

Analyst Coverage: Citigroup has been a brokerage house following shares of Dermira, Inc. (DERM), so its rating change is noteworthy. The stock was upgraded to Buy from Neutral, wrote analysts at Citigroup, in a note issued to clients on Friday December 18, 2015. There was another key note issued by Needham on Tuesday October 28, 2014. The firm launched coverage on DERM at Buy.

Price Momentum: Despite the -1.36% decrease in value, the stock’s new closing price represents a -16.64% fall in value from company’s one year high of $35.75. The stock is currently holding above its 50 day moving average of $12.17 and above its 200 day moving average of $28.21. Over the last three months and over the last six months, the shares of Dermira, Inc. (DERM), have changed 11.39% and 26.74%, respectively.

 

TransEnterix, Inc. (NYSEMKT:TRXC): Updated Analyst Ratings

TransEnterix, Inc. (TRXC) down -19.15 per cent in the past week, is under coverage of 7 analysts who collectively recommend a hold rating on stock. 5 of the analysts have a buy or better rating; the 0 sells versus 0 underperforms. The 7 equity analysts who rate the stock have an average target price at $3.75, with individual targets ranging between $2 and $6. The shares closed last trade at $1.52, implying that analysts see shares rising about 146.71 per cent in 12 months’ time.

Insider Activity: Insiders look optimistic about the prospects of the company that they seem to accumulate shares while they are -38.71 down so far this year. A EVP and CFO at TransEnterix, Inc. (TRXC) purchased shares in the company in a transaction completed on Friday May 13, 2016. Slattery Joseph P accumulated 50,000 shares in the company at an average price of $1.92 and ended up spending $96,000 in the investment. Slattery Joseph P now have 197,387 shares in the company after this transaction. A Director in the company, Biffi Andrea, on Monday November 16, 2015 spent $70,250 from the purchase of 25,000 shares at $1.92 each. Insiders are expected to know better about the health and prospects of their company, which is why insiders’ move deserves attention.

Earnings to Watch: Investors considering TRXC stock at the going market price of $1.52/share should know the stock will next release quarterly results for the June 2016 quarter. For the reporting quarter, analysts expect the company to deliver -$0.15 in earnings per share (EPS). That would represent a 7.14% year-over-year increase. Revenue for the same period is expected to arrive at $1.07M.

Earnings Roundup: In the last fiscal quarter alone, TransEnterix, Inc. generated around $0 in revenue and net income of -$0.12/share. That compares with the consensus estimate $450000 and -$0.13/share, respectively. For the prior quarter revenue for the company hit $0, with earnings at -$0.13/share.

Analyst Coverage: Lake Street has been a brokerage house following shares of TransEnterix, Inc. (TRXC), so its rating change is noteworthy. The stock was downgraded to Hold from Buy, wrote analysts at Lake Street, in a note issued to clients on Wednesday May 11, 2016. There was another key note issued by RBC Capital Mkts on Tuesday May 27, 2014. The firm launched coverage on TRXC at Outperform.

Price Momentum: Despite the -3.8% decrease in value, the stock’s new closing price represents a -75.08% fall in value from company’s one year high of $6.1. The stock is currently holding above its 50 day moving average of $-47.36 and below its 200 day moving average of $1.9. Over the last three months and over the last six months, the shares of TransEnterix, Inc. (TRXC), have changed -46.02% and 2.94%, respectively.

 

The Insider Activity Don’t Lie: Kohl’s Corp. (NYSE:KSS)

Kohl’s Corp. (KSS) up 6.95 per cent in the past week, is under coverage of 24 analysts who collectively recommend a hold rating on stock. 8 of the analysts have a buy or better rating; the 0 sells versus 4 underperforms. The 22 equity analysts who rate the stock have an average target price at $41, with individual targets ranging between $31 and $66. The shares closed last trade at $38.04, implying that analysts see shares rising about 7.78 per cent in 12 months’ time.

Insider Activity: Insiders look pessimistic about the prospects of the company that they seem to offload shares while they are -18.21 down so far this year. A CFO at Kohl’s Corp. (KSS) sold shares in the company in a transaction completed on Friday April 01, 2016. Mcdonald Wesley S offloaded 5,591 shares in the company at an average price of $46.47 and ended up generating $259,810 in proceeds. Mcdonald Wesley S retains 88,153 shares in the company after this transaction. A CFO in the company, Mcdonald Wesley S, on Tuesday March 29, 2016 collected $77,300 from the sale of 1,645 shares at $46.47 each. Insiders are expected to know better about the health and prospects of their company, which is why insiders’ move deserves attention.

Earnings to Watch: Investors considering KSS stock at the going market price of $38.04/share should know the stock will next release quarterly results for the July 2016 quarter. For the reporting quarter, analysts expect the company to deliver $1.03 in earnings per share (EPS). That would represent a -3.74% year-over-year decrease. Revenue for the same period is expected to arrive at $4.17B.

Earnings Roundup: In the last fiscal quarter alone, Kohl’s Corp. generated around $3.97B in revenue and net income of $0.31/share. That compares with the consensus estimate $4.13B and $0.37/share, respectively. For the prior quarter revenue for the company hit $6.39B, with earnings at $1.58/share.

Analyst Coverage: RBC Capital Mkts has been a brokerage house following shares of Kohl’s Corp. (KSS), so its rating change is noteworthy. The stock was initiated at Underperform, wrote analysts at RBC Capital Mkts, in a note issued to clients on Wednesday May 04, 2016. There was another key note issued by Miller Tabak on Thursday March 31, 2016. The firm launched coverage on KSS at Buy.

Price Momentum: Despite the 1.87% increase in value, the stock’s new closing price represents a -39.15% fall in value from company’s one year high of $65.2. The stock is currently holding above its 50 day moving average of $-6.86 and below its 200 day moving average of $39.83. Over the last three months and over the last six months, the shares of Kohl’s Corp. (KSS), have changed -14.83% and 44.86%, respectively.